ArticleOpen forum infectious diseases2025
Intersecting Risk Factors Associated With High Syphilis Seroprevalence Among a Street-Involved Population in Canada.
Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluating the MedMira Multiplo® Complete Syphilis (TP/nTP) antibody test in a sexually transmitted infection clinic in Ottawa, Canada: increased rapid diagnosis and improved antibiotic stewardship.BMC infectious diseases · 2025Trial
- Utilization and Performance of a Rapid Treponemal Antibody Test for Diagnosis of Syphilis in a High-Risk Population at an Urban County Hospital.Sexually transmitted diseases · 2026Article
- Syphilis Infections Among Women of Reproductive Age in the Southern United States: An Analysis From the Study of Treatment and Reproductive Outcomes (STAR).Open forum infectious diseases · 2026Article
- Technological innovations and breakthrough pathways in syphilis diagnosis: addressing global resurgence and the journey toward elimination.Frontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Syphilis has reemerged as a global public health concern. In Ontario, Canada's most populous province, a 340% increase in infectious syphilis cases was observed between 2013 and 2023. This surge was accompanied by a demographic shift, with women emerging as the fastest-growing at-risk group. We examined intersecting risk factors associated with syphilis seropositivity among a street-involved population. Methods: Data were collected from the Syphilis Point of Care Rapid Test and Immediate Treatment Evaluation (SPRITE) study-an outreach model of care implemented by 8 public health units (PHUs) across Ontario between 2023 and 2024. Reactive treponemal antibodies defined syphilis seroprevalence. A mixed-effects regression with a log-binomial distribution was used to evaluate the association between risk factors and seropositivity. Adjusted prevalence ratio (aPR) controlled for age and sex and clustering by PHUs. Results: A total of 630 participants, 42% women, with a median age of 38, were included; 19.1% of participants reported having sexual risk factors, using illicit drugs, and being un(der)housed. Overall, syphilis seroprevalence was 7.6% (95% confidence interval 5.5-9.7), with significant heterogeneity across the province and higher among those reporting 3 risk factors (19.2% [11.2-29.7]) compared with 1 risk factor (4.8% [1.8-10.1]). Seropositivity was higher among women (aPR 1.62 [.94-2.80]) and people who use illicit drugs (aPR 2.30 [.93-5.50]), particularly those who use crystal methamphetamine (aPR 2.88 [1.31-6.33]). Conclusions: Syphilis is heightened at the intersection of sexual risk factors, illicit drug use, and housing instability among equity-deserving populations. Targeted outreach models of care are necessary to reach this emerging at-risk population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.